Ty -jour t1-遵守5年CPAP治疗后睡眠呼吸暂停患者的癌症风险JF-欧洲呼吸杂志- Gervès-Pinquié, Chloé AU - Trzepizur, Wojciech AU - Meslier, Nicole AU - Goupil, François AU - Pigeanne, Thierry AU - Launois, Sandrine AU - Leclair-Visonneau, Laurene AU - Masson, Philippe AU - Bizieux-Thaminy, AcyaAu -Racineux，Jean -Louis au -Gozal，David Au -Gagnadoux，FrédéricA2-，Y1-2021/01/01 Ur -http：//http：//www.qdcxjkg.com/content/content/content/early/early/2021/08/08/12/12/12/139933003.08/12/13993355-2021.Abstract N2-越来越多的证据表明，阻塞性睡眠呼吸暂停（OSA）会导致癌症风险；但是，关于连续阳性气道压力（CPAP）治疗对癌症发生率的影响有限的数据。我们的目的是确定与非依从性OSA患者相比，遵守CPAP治疗是否与降低全癌发病率有关。方法依赖于多中心研究收集的数据支付与健康有关的数据，该研究与健康有关，与健康有关行政数据，例如鉴定新的癌症。我们纳入了因OSA开具CPAP的患者，在诊断睡眠研究之前或CPAP的第一年没有癌症史。CPAP使用文献至少每晚4小时的患者被定义为依从性。那些在夜间停止或使用CPAP少于4小时的人构成了非遵守组。进行了倾向评分的倾向分析概率，以评估CPAP依从性对癌症风险的影响。中位数[四分位间范围]的后续后续5.4 [3.1-8.0]年，437年（9.7％）（9.7％） of 4,499 patients developed cancer, 194 (10.7%) in the non-adherent group (n=1817) and 243 (9.1%) in adherent patients (n=2682). The final weighted model showed no significant impact of CPAP adherence on all-cause cancer risk (sub distribution hazard ratio [95% confidence interval]): 0.94 [0.78; 1.14]).Conclusions Adherence to CPAP therapy in OSA patients was not associated with a reduction in all-cancer incidence. Whether adherent CPAP therapy of OSA might reduce the risk of specific cancer sites should be further evaluated.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Grégoire Justeau has nothing to disclose.Conflict of interest: S. Bailly reports Consulting fees for methodology and statistical analyses from ISRS Pays de la Loire, outside the submitted work.Conflict of interest: Chloé Gervès-Pinquié has nothing to disclose.Conflict of interest: Wojciech Trzepizur has nothing to disclose.Conflict of interest: Nicole Meslier has nothing to disclose.Conflict of interest: François Goupil has nothing to disclose.Conflict of interest: Thierry Pigeanne has nothing to disclose.Conflict of interest: Sandrine Launois has nothing to disclose.Conflict of interest: Laurene Leclair-Visonneau has nothing to disclose.Conflict of interest: Philippe Masson has nothing to disclose.Conflict of interest: Acya Bizieux-Thaminy has nothing to disclose.Conflict of interest: Jean-Louis Racineux has nothing to disclose.Conflict of interest: D. Gozal reports NIH grants outside the submitted work. All other authors have nothing to disclose.Conflict of interest: F. Gagnadoux reports support for the present manuscript from Institut Recherche en Santé Respiratoire des Pays de la Loire to University Hospital of Angers; consulting fees from NYXOAH, SEFAM and RESMED; payment or honoraria for lectures from CIDELEC, ASTEN SANTE and BOEHRINGER INGELHEIM; payment for expert testimony from BOEHRINGER INGELHEIM; support for attending meetings and/or travel from ASTEN SANTE and ACTELION; participation on a Data Safety Monitoring Board or Advisory Board for JAZZ PHARMACEUTICAL; receipt of equipment, materials, drugs, medical writing, gifts or other services from INSPIRE to University Hospital of Angers, outside the present work. ER -